Literature DB >> 15274392

Expression of betacellulin, heparin-binding epidermal growth factor and epiregulin in human malignant fibrous histiocytoma.

Tetsuji Yamamoto1, Toshihiro Akisue, Takashi Marui, Tetsuya Nakatani, Teruya Kawamoto, Toshiaki Hitora, Keiko Nagira, Ikuo Fujita, Keiji Matsumoto, Masahiro Kurosaka.   

Abstract

BACKGROUND: Heparin-binding epidermal growth factor (HB-EGF), betacellulin (BTC) and epiregulin (EPR) are members of the EGF system and involved in the cell growth of various epithelial malignancies. There have been no reports on the HB-EGF, BTC and EPR expression in mesenchymal malignancies of fibrohistiocytic origin including malignant fibrous histiocytoma (MFH).
MATERIALS AND METHODS: We investigated the expression of HB-EGF, BTC, EPR and EGF-receptor (EGF-R) in 43 human MFH tissue samples using immunohistochemical techniques.
RESULTS: Positive immuno-reactivity for HB-EGF, BTC, EPR and EGF-R was identified in 28 (65%), 7 (16%), 43 (100%) and 36 (84%) out of the 43 MFH cases analyzed, respectively. Coexpression of HB-EGF/BTC, BTC/EPR and HB-EGF/EPR was observed in 6 (14%), 7 (16%) and 28 (65%) of the MFHs, respectively. Coexpression of HB-EGF/EGF-R, BTC/EGF-R and EPR/EGF-R was observed in 25 (58%), 6 (14%) and 36 (84%) of the MFHs, respectively.
CONCLUSION: These results revealed that HB-EGF, BTC and EPR are expressed not only by epithelial tumor cells, but also by MFH cells. It is suggested that HB-EGF and EPR might be more important tumor growth regulators of MFH through autocrine or paracrine pathways, when compared with BTC.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15274392

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Epiregulin: roles in normal physiology and cancer.

Authors:  David J Riese; Richard L Cullum
Journal:  Semin Cell Dev Biol       Date:  2014-03-12       Impact factor: 7.727

2.  Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas.

Authors:  Shaowei Li; Fumiko Takeuchi; Ji-An Wang; Qingyuan Fan; Toshi Komurasaki; Eric M Billings; Gustavo Pacheco-Rodriguez; Joel Moss; Thomas N Darling
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-21       Impact factor: 11.205

3.  Cholesteatoma fibroblasts promote epithelial cell proliferation through overexpression of epiregulin.

Authors:  Mamoru Yoshikawa; Hiromi Kojima; Yuichiro Yaguchi; Naoko Okada; Hirohisa Saito; Hiroshi Moriyama
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

4.  The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines.

Authors:  Darren Chyi-Hsiang Kong; Kenneth Yee Choy Chew; Eng Lai Tan; Suan Phaik Khoo
Journal:  Cancer Cell Int       Date:  2014-11-18       Impact factor: 5.722

5.  Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.

Authors:  N Takahashi; Y Yamada; K Furuta; Y Honma; S Iwasa; A Takashima; K Kato; T Hamaguchi; Y Shimada
Journal:  Br J Cancer       Date:  2014-05-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.